Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2024Open Access

The Pan-immune-inflammation Value Predicts the Survival of Patients with Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XQXiaoyan QiTSTingting SongDHDan Huang

Discussion

Loading...

Member takes

Overview

Meta-analysis demonstrates reduced survival in breast cancer patients with elevated pan-immune-inflammation value, highlighting its clinical utility as a prognostic biomarker.

Key Points

  • Elevated pan-immune-inflammation value significantly associates with reduced overall survival, and it corresponds to worse progression-free survival in breast cancer.
  • Meta-analysis shows an overall survival hazard ratio of 1.841 across 2,744 breast cancer cases, confirming significantly worse outcomes for high inflammatory markers.
  • Highlights pan-immune-inflammation value as a promising prognostic biomarker, while higher scores also correlate with poorer response to neoadjuvant chemotherapy.

Cite This Study

Qi et al. (2024) studied this question.

synapsesocial.com/papers/68e7045db6db64358767e689https://doi.org/10.21203/rs.3.rs-2681685/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 114,173 citations
  2. 2Current and future burden of breast cancer: Global statistics for 2020 and 20402022 · 3,379 citations
  3. 3The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study2017 · 115 citations
  4. 4Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis2020 · 97 citations